GGHC
PHAT icon

Gilder Gagnon Howe & Co’s Phathom Pharmaceuticals PHAT Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.55M Sell
139,889
-5,285
-4% -$66.8K 0.02% 209
2025
Q4 		$2.41M Buy
145,174
+56,632
+64% +$809K 0.03% 188
2025
Q3 		$1.04M Buy
88,542
+57,184
+182% +$590K 0.01% 218
2025
Q2 		$301K Sell
31,358
-10,208
-25% -$56.5K ﹤0.01% 230
2025
Q1 		$261K Sell
41,566
-44
-0.1% -$267 ﹤0.01% 225
2024
Q4 		$338K Sell
41,610
-1,581,273
-97% -$19.6M ﹤0.01% 239
2024
Q3 		$29.3M Buy
1,622,883
+150,624
+10% +$2.11M 0.35% 70
2024
Q2 		$15.2M Buy
1,472,259
+454,642
+45% +$4.68M 0.19% 98
2024
Q1 		$10.8M Sell
1,017,617
-437,515
-30% -$3.72M 0.14% 114
2023
Q4 		$13.3M Buy
1,455,132
+145,084
+11% +$1.25M 0.18% 105
2023
Q3 		$13.6M Buy
1,310,048
+249,443
+24% +$3.42M 0.21% 92
2023
Q2 		$15.2M Buy
1,060,605
+506,776
+92% +$5.84M 0.21% 95
2023
Q1 		$3.95M Buy
553,829
+2,002
+0.4% +$17.6K 0.07% 146
2022
Q4 		$6.19M Sell
551,827
-615
-0.1% -$6.34K 0.12% 126
2022
Q3 		$6.12M Sell
552,442
-3,663
-0.7% -$34.9K 0.11% 123
2022
Q2 		$4.69M Sell
556,105
-188
-0% -$1.93K 0.08% 138
2022
Q1 		$7.57M Buy
556,293
+10,238
+2% +$165K 0.07% 154
2021
Q4 		$10.7M Sell
546,055
-4,185
-0.8% -$98.5K 0.06% 174
2021
Q3 		$17.7M Buy
550,240
+3,718
+0.7% +$124K 0.09% 164
2021
Q2 		$18.5M Sell
546,522
-271,863
-33% -$9.74M 0.09% 167
2021
Q1 		$30.7M Buy
+818,385
New +$34.2M 0.17% 129

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Gilder Gagnon Howe & Co's PHAT Position: Q1 2026 in Review

Gilder Gagnon Howe & Co reduced its Phathom Pharmaceuticals (PHAT) stake by 3.6% in Q1 2026, selling an estimated $66.8K and leaving 139,889 shares worth $1.55M. The position accounts for 0.02% of the portfolio, ranked #209.

Gilder Gagnon Howe & Co first reported a position in PHAT in Q1 2021 and has held it in 21 quarters since. The position peaked at $30.7M in Q1 2021. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Gilder Gagnon Howe & Co held 139,889 shares of Phathom Pharmaceuticals worth $1.55M as of Q1 2026.
  • Gilder Gagnon Howe & Co sold 5,285 Phathom Pharmaceuticals shares in Q1 2026, an estimated $66.8K.
  • Phathom Pharmaceuticals made up 0.02% of Gilder Gagnon Howe & Co's portfolio in Q1 2026, its #209 holding.
  • Gilder Gagnon Howe & Co first reported a position in Phathom Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • Gilder Gagnon Howe & Co's Phathom Pharmaceuticals position peaked at $30.7M in Q1 2021.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2026, filed 15 May 2026.